A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
24 participants
Apr 30, 2026
INTERVENTIONAL
Conditions
Summary
This study is a single arm, open label, dose exploring clinical study to evaluate the safety, efficacy, metabolic kinetics and pharmacodynamics of CT1182 cells in patients with relapsed / refractory B-cell non Hodgkin lymphoma (r/r B-NHL).
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
CT1182 injection is an in vivo car-t product (CT1182) independently developed by carsgen company based on carvivo ™ platform, which simultaneously targets CD19 and CD20. Carvivo ™ platform uses redirected lentiviral vector technology to directly target and transduce T cells and generate functional car-t cells in vivo after intravenous infusion of lentivirus to achieve specific targeted killing of tumor cells. The CT1182 product adopts an optimized mutant engineered vesicular stomatitis virus (VSV) envelope, which makes the lentivirus lose its pan tropism. At the same time, it loads redirected CD3 targeting molecules on the virus surface to achieve specific transduction of T cells.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07548697